News Releases

Email Alerts

May 16, 2018

Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC

PDUFA Action Date Set for September 28, 2018

BRIDGEWATER, N.J., May 16, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today...
May 2, 2018

Insmed Reports First Quarter 2018 Financial Results and Provides Business Update

Submitted NDA to FDA for Amikacin Liposome Inhalation Suspension (ALIS) in NTM lung disease caused by MAC; anticipates priority review

BRIDGEWATER, N.J., May 02, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported...
May 1, 2018

Insmed to Present at the Deutsche Bank 43rd Annual Health Care Conference

BRIDGEWATER, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Apr 25, 2018

Insmed to Host First Quarter 2018 Financial Results Conference Call on Wednesday, May 2, 2018

BRIDGEWATER, N.J., April 25, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
Mar 29, 2018

Insmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MAC

ALIS previously designated as an orphan drug, breakthrough therapy and Qualified Infectious Disease Product (QIDP)

BRIDGEWATER, N.J., March 29, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
Mar 7, 2018

Insmed to Present at the Cowen and Company 38th Annual Health Care Conference

BRIDGEWATER, N.J., March 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
Feb 23, 2018

Insmed Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

On track to file NDA before the end of March and anticipate a priority review

BRIDGEWATER, N.J., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported...
Feb 21, 2018

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
Feb 20, 2018

Insmed Extends ALIS Intellectual Property Protection to 2035 with Issuance of Ninth U.S. Patent

BRIDGEWATER, N.J., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
Feb 15, 2018

Insmed to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Friday, February 23, 2018

BRIDGEWATER, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...

Show per page